Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
Supplemental Information – Table & Figures
TIRZEPATIDE (COAGONISTA GIP/GP1): DESARROLLO CLINICO SURPASS
Efficacy and safety of three dose-escalation algorithms of tirzepatide, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes - Media Centre | EASD
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect | Cardiovascular Diabetology | Full Text
Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing | Organic Process Research & Development
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
cardio-met on Twitter: "From mice models GIP only lowers glucose when glucose close to normal (data not shown) In GLP-1 knockout mice Tirzepatide is much better at weight loss compared to semaglutide
Molecules | Free Full-Text | Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review
DIABETES | New Drug Approvals
IJMS | Free Full-Text | Tirzepatide: A Systematic Update
Lilly's GLP-1 and Tirzepatide initiates phase III clinical trial
Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial - The Lancet
Frontiers | Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
tirzepatide | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Tirzepatide (LY3298176)
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes | NEJM
Tirzepatide - an overview | ScienceDirect Topics
Structural determinants of dual incretin receptor agonism by tirzepatide | PNAS
Once-weekly tirzepatide versus once-daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): a randomised, open-label, parallel-group, phase 3 trial - The Lancet
Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors | Nature Communications
The novel dual GIP and GLP-1 receptor agonist, tirzepatide, transiently delays gastric emptying similarly to a selective long-acting GLP-1 receptor agonist - Media Centre | EASD
Tirzepatide: A Novel, Once-weekly Dual GIP and GLP-1 Receptor Agonist for the Treatment of Type 2 Diabetes – touchENDOCRINOLOGY
Structural determinants of dual incretin receptor agonism by tirzepatide | PNAS
